Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Liabilities and Shareholders Equity (2021 - 2025)

Bioregenx has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $410986.0 for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 19.18% year-over-year to $410986.0; the TTM value through Dec 2025 reached $3.2 million, down 94.09%, while the annual FY2025 figure was $410986.0, 19.18% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $410986.0 at Bioregenx, down from $1.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $18.6 million in Q1 2024 and troughed at $33981.0 in Q3 2023.
  • A 5-year average of $4.2 million and a median of $495579.0 in 2024 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 50991.39% in 2024 and later crashed 97.41% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $127762.0 in 2021, then tumbled by 53.7% to $59149.0 in 2022, then soared by 1363.68% to $865750.0 in 2023, then plummeted by 41.26% to $508535.0 in 2024, then dropped by 19.18% to $410986.0 in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for BRGX at $410986.0 in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.